Integra Lifesciences Holdings (IART) Long-Term Deferred Tax (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Long-Term Deferred Tax data on file, last reported at $68.1 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 79.11% year-over-year to $68.1 million; the trailing twelve-month figure through Mar 2026 stood at $68.1 million (up 79.11% YoY), and the FY2025 full-year result was $69.9 million, up 100.02% from the prior year.
• Long-Term Deferred Tax eased to $68.1 million in Q1 2026, from $69.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $109.7 million in Q3 2025 to a low of $34.2 million in Q1 2024.
• A 5-year average of $56.1 million and a median of $48.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax tumbled 43.61% in 2022 and soared 124.95% in 2025, its largest moves.
• Tracing IART's Long-Term Deferred Tax over 5 years: stood at $46.0 million in 2022, then climbed by 0.19% to $46.1 million in 2023, then retreated by 24.21% to $34.9 million in 2024, then surged by 100.02% to $69.9 million in 2025, then dropped by 2.54% to $68.1 million in 2026.
• Business Quant data shows IART's Long-Term Deferred Tax at $68.1 million in Q1 2026, $69.9 million in Q4 2025, and $109.7 million in Q3 2025.